189 related articles for article (PubMed ID: 19810096)
1. Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer.
Tominaga T; Iwahashi M; Takifuji K; Hotta T; Yokoyama S; Matsuda K; Higashiguchi T; Oku Y; Nasu T; Yamaue H
Int J Cancer; 2010 Apr; 126(7):1691-701. PubMed ID: 19810096
[TBL] [Abstract][Full Text] [Related]
2. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
[TBL] [Abstract][Full Text] [Related]
3. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
[TBL] [Abstract][Full Text] [Related]
4. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX.
Nehls O; Okech T; Hsieh CJ; Enzinger T; Sarbia M; Borchard F; Gruenagel HH; Gaco V; Hass HG; Arkenau HT; Hartmann JT; Porschen R; Gregor M; Klump B
Br J Cancer; 2007 May; 96(9):1409-18. PubMed ID: 17426704
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Mirjolet JF; Barberi-Heyob M; Didelot C; Peyrat JP; Abecassis J; Millon R; Merlin JL
Br J Cancer; 2000 Nov; 83(10):1380-6. PubMed ID: 11044365
[TBL] [Abstract][Full Text] [Related]
6. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
[TBL] [Abstract][Full Text] [Related]
7. The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells.
Zheng M; Wang H; Zhang H; Ou Q; Shen B; Li N; Yu B
J Cancer Res Clin Oncol; 1999; 125(6):357-60. PubMed ID: 10363568
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
[TBL] [Abstract][Full Text] [Related]
9. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
[TBL] [Abstract][Full Text] [Related]
10. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
[TBL] [Abstract][Full Text] [Related]
11. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
Cohen V; Panet-Raymond V; Sabbaghian N; Morin I; Batist G; Rozen R
Clin Cancer Res; 2003 May; 9(5):1611-5. PubMed ID: 12738713
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs.
Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
Oncol Rep; 2005 Sep; 14(3):609-15. PubMed ID: 16077963
[TBL] [Abstract][Full Text] [Related]
13. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins.
Nita ME; Nagawa H; Tominaga O; Tsuno N; Fujii S; Sasaki S; Fu CG; Takenoue T; Tsuruo T; Muto T
Br J Cancer; 1998 Oct; 78(8):986-92. PubMed ID: 9792140
[TBL] [Abstract][Full Text] [Related]
15. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.
Nishida N; Yamashita S; Mimori K; Sudo T; Tanaka F; Shibata K; Yamamoto H; Ishii H; Doki Y; Mori M
Ann Surg Oncol; 2012 Sep; 19(9):3065-71. PubMed ID: 22322955
[TBL] [Abstract][Full Text] [Related]
17. Nobiletin induces apoptosis and potentiates the effects of the anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric cancer cells.
Moon JY; Cho M; Ahn KS; Cho SK
Nutr Cancer; 2013; 65(2):286-95. PubMed ID: 23441616
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy.
Huang ZH; Hua D; Li LH; Zhu JD
J Cancer Res Clin Oncol; 2008 Oct; 134(10):1129-34. PubMed ID: 18357466
[TBL] [Abstract][Full Text] [Related]
20. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas.
Benhattar J; Cerottini JP; Saraga E; Metthez G; Givel JC
Int J Cancer; 1996 Jun; 69(3):190-2. PubMed ID: 8682586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
